Corbion

INDUSTRY RELEASE

Corbion
Arkelsedijk 46
Gorinchem, 4206 AC • PO Box 21
4200 AA Gorinchem
The Netherlands

T +31183 695 695
F +31183 695 602

www.corbion.com/biochemicals

PRESS RELEASE

DATE 8th July 2022

Smart Biomaterials Consortium (SBMC) members announce first collaboration to prevent thousands of amputations worldwide

STENTiT, Vivolta and Corbion announced their first collaboration to develop a regenerative stent for clinical use, with an initial focus on the treatment of patients suffering from critical limb ischemia. The announcement by members of SBMC was made at the RegMed XB Pilot Factory Meeting held at the Philips Stadium in Eindhoven, Netherlands.

The project proposal will enable translational steps needed to move the regenerative stent another step closer towards clinical application. STENTiT, Vivolta and Corbion are collaborating for the ultimate purpose of manufacturing batches of clinical-grade stents together.

The first indication targeted for application of the regenerative stent is the treatment of patients suffering from critical limb ischemia, a progressive form of peripheral artery disease in which blood flow to the foot is severely compromised. With the regenerative stent, the consortium partners aim to provide a solution that instantly restores blood flow to the foot using an endovascular support device composed of bioresorbable nanofibers capable of regenerating the artery from within.

Since the device is composed solely of bioresorbable nanofibers, its porous structure will allow the influx of circulating blood cells, triggering a natural healing response by which new vascular tissue is rebuilt. In this way, the implant facilitates vascular regeneration to restore the affected artery from the inside out, then subsequently resorbs safely over time.

The initiative aims to provide superior long-term clinical outcomes and to prevent hundreds of thousands of amputations worldwide each year. This project fits into the scope of RegMedXB and SBMC by using smart biomaterials to create endovascular band-aids that can persuade the body to regenerate affected blood vessels.

[Photo f.l.t.r: Jan Rietsema, CEO Smart Biomaterials Consortium (SBMC);
Judit Canadell-Ayats, Principal Scientist/Group leader Product Development Corbion,
Bart Sanders, CEO & co-founder STENTiT and Ramon Solberg, CEO a.i., CTO & Founder at Vivolta.]

PRESS RELEASE

For more information, please contact:

Press:
Anna Sobczak, Senior Marketing Manager
+31 (0)183 695 695, a.sobczak@corbion.com

Analysts and investors:
Jeroen van Harten, Director Investor Relations
+31 (0)20 590 6293, +31(0)6 21 577 086

Background information:

About Corbion
Corbion is the global market leader in lactic acid and its derivatives, and a leading supplier of emulsifiers, functional enzyme blends, minerals, vitamins, and algae ingredients. We use our unique expertise in fermentation and other processes to deliver sustainable solutions for the preservation of food and food production, health, and our planet. For over 100 years, we have been uncompromising in our commitment to safety, quality, innovation and performance. Drawing on our deep application and product knowledge, we work side-by-side with customers to make our cutting-edge technologies work for them. Our solutions help differentiate products in markets such as food, home & personal care, animal nutrition, pharmaceuticals, medical devices, and bioplastics. In 2021, Corbion generated annual sales of € 1.070,8 million and had a workforce of 2,493 FTE. Corbion is listed on Euronext Amsterdam.
For more information: www.corbion.com

About STENTiT
STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These bioresorbable devices trigger a natural healing response by the circulating blood cells, in which the implant is being replaced by new vascular tissue to restore the artery from the inside-out. Since the establishment of the company in 2017, STENTiT has received broad international recognition and awards for its high-potential approach, covering world leading stages. As the company is currently going through the next translational phases, STENTiT is on its way to fulfill its ambition to become the new standard in endovascular treatment, providing a life-lasting solution for millions of patients around the world.
For more information: www.stentit.com

About VIVOLTA
VIVOLTA offers the MedTech and Pharma industry groundbreaking nanofiber-based solutions that guide the human body to heal itself. We enable patients, suffering from an impaired quality of life due to congenital defects, trauma or aging, to benefit from the most innovative and sustainable medical solutions. As thought leader, VIVOLTA is setting the worldwide standard for electrospun nanofiber-based medical devices, tissue engineering products, and drug delivery solutions. Utilizing its fully automated MediSpin® technology platform, production of VIVOLTA's solutions is both consistent, reproducible and scalable. Importantly, the MediSpin® platform, protected by seven patent families, meets the guidelines described in the first ASTM standard for fiber-based medical scaffolds (F3510-21), which VIVOLTA co-authored.
For more information: www.vivolta.com

Corbion

PRESS RELEASE

About Smart Biomaterials Consortium
The Smart Biomaterials Consortium (SBMC) Foundation is developing a high-quality infrastructure of a production ecosystem for bio- and biocompatible materials for use in regenerative medicine. This form of medicine is aimed at developing new treatments that make smart use of the self-healing capacity of our body. The SBMC Foundation is realizing a development facility on the Eindhoven University of Technology campus and a pilot production facility. The 'pilot factory' for regenerative medicine is being built as part of the growth fund program RegMed XB.
For more information: www.smartbiomaterials.nl

About RegMedXB
RegMed XB stands for Regenerative Medicine Crossing Borders. RegMed XB is a public-private partnership dedicated to bringing regenerative medicine solutions to patients and creating a new industrial sector in the participating regions. RegMed XB brings together some 500 leading scientists at Dutch and Belgian universities and institutes and a range of companies in so-called “Moonshots”: long-term visions of breakthroughs for patients, translated into research roadmaps with specific short-term milestones. There are currently four Moonshots (kidney, diabetes, osteoarthritis, and cardiovascular). Each is championed by a Health Foundation and their related patient organizations, putting patient impact at the heart of RegMed XB.
For more information: www.regmedxb.com